It's up from here.....analysts have an avg $10 PT on TSRX.
BAC/Merrill Lynch has a BUY on this stock and that's one of the reasons why I bought in, they are very conservative...TRIUS is undervalued with catalyts to push it higher. The seeking alpha article yesterday was spot on when the author said TSRX is a buy under $20.
-Trius Therapeutics announces publication of Tedizolid ESTABLISH 1 Trial in JAMA; Tedizolid achieves All FDA and EMA endpoints in first Phase 3 trial conducted under new draft guidance for acute bacterial skin and skin structure infe
Sentiment: Strong Buy